Literature DB >> 20218988

Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.

P A Chan1, N T Connell, A M Gabonay, B Westley, J M Larkin, S P LaRosa, K Chapin, L Mermel.   

Abstract

Although neuraminidase inhibitors are active against most 2009-2010 pandemic influenza A (H1N1) swine-origin strains, sporadic cases of oseltamivir resistance have been described. Since April 2009, 54 cases of oseltamivir-resistant H1N1 swine-origin have been reported in the USA (http://www.cdc.gov/flu/weekly/; accessed 1 February 2010). Approximately 1.4% of tested isolates are oseltamivir resistant. We report a patient with an underlying hematological malignancy who was hospitalized with influenza A (H1N1) swine-origin and whose strain developed oseltamivir resistance during therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20218988     DOI： 10.1111/j.1469-0691.2010.03212.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  11 in total

1.  Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.

Authors:  Elodie Ghedin; Jennifer Laplante; Jay DePasse; David E Wentworth; Roberto P Santos; Martha L Lepow; Joanne Porter; Kathleen Stellrecht; Xudong Lin; Darwin Operario; Sara Griesemer; Adam Fitch; Rebecca A Halpin; Timothy B Stockwell; David J Spiro; Edward C Holmes; Kirsten St George
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

Review 2.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

Review 3.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

4.  A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.

Authors:  E Bart Tarbet; Stephanie Hamilton; Almut H Vollmer; Angela Luttick; Wy Ching Ng; Melinda Pryor; Brett L Hurst; Simon Crawford; Donald F Smee; Simon P Tucker
Journal:  J Antimicrob Chemother       Date:  2014-04-28       Impact factor: 5.790

5.  I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.

Authors:  Jérome LeGoff; Dominique Rousset; Georges Abou-Jaoudé; Anne Scemla; Patricia Ribaud; Séverine Mercier-Delarue; Valérie Caro; Vincent Enouf; François Simon; Jean-Michel Molina; Sylvie van der Werf
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

6.  Drug-resistant pandemic (H1N1) 2009, South Korea.

Authors:  Soo Youn Shin; Chun Kang; Jin Gwack; Joon Hyung Kim; Hyun Su Kim; Young A Kang; Ha Gyung Lee; Jin Seok Kim; Jong Koo Lee; Sung Han Kim
Journal:  Emerg Infect Dis       Date:  2011-04       Impact factor: 6.883

7.  Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments.

Authors:  Vladimir V Zarubaev; Angelica V Garshinina; Nelly A Kalinina; Anna A Shtro; Svetlana V Belyaevskaya; Alexander V Slita; Vladimir E Nebolsin; Oleg I Kiselev
Journal:  Pharmaceuticals (Basel)       Date:  2011-11-25

8.  Report of the 'mechanisms of lung injury and immunomodulator interventions in influenza' workshop, 21 March 2010, Ventura, California, USA.

Authors:  Wendy A Howard; Malik Peiris; Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2011-08-17       Impact factor: 4.380

Review 9.  Drug resistance in influenza A virus: the epidemiology and management.

Authors:  Mazhar Hussain; Henry D Galvin; Tatt Y Haw; Ashley N Nutsford; Matloob Husain
Journal:  Infect Drug Resist       Date:  2017-04-20       Impact factor: 4.003

10.  Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus.

Authors:  Miguelmiguel Quiliano; Hugo Valdivia-Olarte; Carlos Olivares; David Requena; Andrés H Gutiérrez; Paola Reyes-Loyola; Luis E Tolentino-Lopez; Patricia Sheen; Verónica Briz; Maria A Muñoz-Fernández; José Correa-Basurto; Mirko Zimic
Journal:  Bioinformation       Date:  2013-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.